Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 5, 2010, Pages 661-666

  White, Caitlin M ^a   Ji, Sunggoan ^a   Cai, Huan ^a   Maudsley, Stuart ^a   Martin, Bronwen ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; Autism spectrum disorders; Neurological disorders; Parkinson's disease; Pharmacotherapeutics; Pituitary adenylate cyclase activating peptide; Vasoactive intestinal peptide

Indexed keywords

BAY 559837; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE[6-38]; MAXADILAN; PG 97269; PG 99465; RO 251553; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VASOACTIVE INTESTINAL POLYPEPTIDE[7-28];

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; AUTISM; BINDING AFFINITY; DRUG RECEPTOR BINDING; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; SENILE PLAQUE;

EID: 78649287541     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793361595     Document Type: Article

References (62)

1. Chapter, M.C.; White C.M.; DeRidder, A.; Chadwick, W.; Martin, B.; Maudsley, S. Chemical modification of Class II G proteincoupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol. Ther., 2010, 125(1), 39-54.
2. Said, S.I.; Mutt, V. Polypeptide with broad biological activity: isolation from small intestine. Science, 1970, 169(951), 1217-1218.
3. Fahrenkrug, J. Transmitter role of vasoactive intestinal peptide. Pharmacol. Toxicol., 1993, 72(6), 354-363.
4. Gozes, I.; Brenneman, D.E. VIP: molecular biology and neurobiological function. Mol. Neurobiol., 1989, 3(4), 201-236.
5. Du, B.H.; Eng, J.; Hulmes, J.D.; Chang, M.; Pan, Y.C.; Yalow, R.S. Guinea pig has a unique mammalian VIP. Biochem. Biophys. Res. Commun., 1985, 128(3), 1093-1098.
6. Nishizawa, M.; Hayakawa, Y.; Yanaihara, N.; Okamoto, H. Nucleotide sequence divergence and functional constraint in VIP mRNA evolution between human and rat. FEBS Lett., 1985, 183(1), 55-59.
7. Itoh, N.; Obata, K.; Yanaihara, N.; Okamoto, H. Human preprovasoactive intestinal peptide contains a novel PHI-27-like peptide, PHM-27. Nature, 1983, 304(5926), 547-549.
8. Dickson, L.; Finlayson, K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther., 2009, 121(3), 294-316.
9. Gonzalez-Rey, E., Varela, N.; Chorny, A.; Delgado, M. Therapeutic approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des., 2007, 13(11), 1113-1139.
10. Gomariz, R.P.; Martinez, C.; Abad, C.; Leceta, J.; Delgado, M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des., 2001, 7(2), 89-111.
11. Delgado, M.; Jonakait, G.M.; Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia, 2002, 39(2), 148-161.
12. Martin, B.; Shin, Y.K.; White, C.M.; Ji, S.; Kim, W.; Carlson, O.D.; Napora, J.K.; Chadwick, W.; Chapter, M.; Waschek, J.A.; Mattson, M.P.; Maudsley, S.; Egan, J.M. Vasoactive intestinal peptide null mice demonstrate enhanced sweet taste preference, dysglycemia and reduced taste bud leptin receptor expression. Diabetes, 2010, 59(5), 1143-1152.
13. Shen, T.; Kaya, N.; Zhao, F.L.; Lu, S.G.; Cao, Y.; Herness, S. Coexpression patterns of the neuropeptides vasoactive intestinal peptide and cholecystokinin with the transduction molecules alpha-gustducin and T1R2 in rat taste receptor cells. Neuroscience, 2005, 130(1), 229-238.
14. Sorg, O.; Magistretti, P.J. Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition. J. Neurosci., 1992, 12(12), 4923-4931.
15. Brenneman, D.E.; Hill, J.M.; Gressens, P.; Gozes, I. Neurotrophic action of VIP: from CNS ontogeny to therapeutic strategy. In: Proinflammatory and Anti-inflammatory Peptides, Said, S.I., Ed.; Marcel Dekker: New York, 1997; pp. 383-408.
16. Dejda, A.; Sokolowska, P.; Nowak, J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep., 2005, 57(3), 307-320.
17. Colwell, C.S.; Michel, S.; Itri, J.; Rodriguez, W.; Tam, J.; Lelievre, V.; Hu, Z.; Liu, X.; Waschek, J.A. Disrupted circadian rhythms in VIP-and PHI-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285(5), R939-R949.
18. Loh, D.H.; Abad, C.; Colwell, C.S.; Waschek, J.A. Vasoactive intestinal peptide is critical for circadian regulation of glucocorticoids. Neuroendocrinology, 2008, 88(4), 246-255.
19. Martin, B; Lopez de Maturana, R.; Brenneman, R.; Walent, T.; Mattson, M.P.; Maudsley, S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromol. Med., 2005, 7(1-2), 3-36.
20. Harmar, A.J.; Arimura, A.; Gozes, I.; Journot, L.; Laburthe, M.; Pisegna, J.R.; Rawlings, S.R.; Robberecht, P.; Said, S.I.; Sreedharan, S.P.; Wank, S.A.; Waschek, J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev., 1998, 50(2), 265-270.
21. Laburthe, M.; Couvineau, A.; Tan, V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides, 2007, 28(9), 1631-1639.
22. Dickson, L.; Aramori, I.; McCulloch, J.; Sharkey, J.; Finlayson, K. A systematic comparison of intracellular cyclic AMP and calcium signaling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology, 2006, 51(6), 1086-1098.
23. McCulloch, D.A.; Lutz, E.M.; Johnson, M.S.; MacKenzie, C.J.; Mitchell, R. Differential activation of phospholipase D by VPAC and PAC1 receptors. Ann. N.Y. Acad. Sci., 2000, 921, 175-185.
24. Arimura, A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol., 1998, 48(5), 301-331.
25. Laburthe, M.; Couvineau, A.; Marie, J.C. VPAC receptors for VIP and PACAP. Recept. Channels, 2002, 8(3-4), 137-153.
26. Harmar, A.J.; Hills, R.A.; Rosser, E.M.; Jones, M.; Buneman, O.P.; Dunbar, D.R.; Greenhill, S.D.; Hale, V.A.; Sharman, J.L.; Bonner, T.I.; Catterall, W.A.; Davenport, A.P.; Delagrange, P.; Dollery, C.T.; Foord, S.M.; Gutman, G.A.; Laudet, V.; Neubig, R.R.; Ohlstein, E.H.; Olsen, R.W.; Peters, J.; Pin, J.P.; Ruffolo, R.R.; Searls, D.B.; Wright, M.W.; Spedding, M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucl. Acids Res., 2009, 37, D680-D685.
27. Reubi, J.C. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N. Y. Acad. Sci., 2000, 921, 1-25.
28. Usdin, T.B.; Bonner, T.I.; Mezey, E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology, 1994, 135(6), 2662-2680.
29. Vertongen, P.; Schiffman, S.N.; Gourlet, P.; Robberecht, P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Ann. N. Y. Acad. Sci., 1998, 865, 412-415.
30. Vaudry, D.; Gonzalez, B.J.; Basille, M.; Yon, L.; Fournier, A.; Vaudry, H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev., 2000, 52(2), 269-324.
31. Sheward, W.J.; Lutz, E.M.; Harmar, A.J. The distribution of vasoactive intestinal peptide 2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience, 1995, 67(2), 409-418.
32. Harmar, A.J.; Sheward, W.J.; Morrison, C.F.; Waser, B.; Gugger, M.; Reubi, J.C. Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology, 2004, 145(3), 1203-1210.
33. Harmar, A.J.; Marston, H.M.; Shen, S.; Spratt, C.; West, K.M.; Sheward, W.J.; Morrison, C.F.; Dorin, J.R.; Piggins, H.D.; Reubi, J.C.; Kelly, J.S.; Maywood, E.S.; Hastings, M.H. The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell, 2002, 109(4), 497-508.
34. Cutler, D.J.; Haraura, M. Reed, H.E.; Shen, S.; Sheward, W.J.; Morrison, C.F.; Marston, H.M.; Harmar, A.J.; Piggins, H.D. The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro. Eur. J. Neurosci., 2003, 17(2), 197-204.
35. Hughes, A.T.; Fahey, B.; Cutler, D.J.; Coogan, A.N.; Piggins, H.D. Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor. J. Neurosci., 2004, 24(14), 3522-3526.
36. Aton, S.J.; Colwell, C.S.; Harmar, A.J.; Waschek, J.; Herzog, E.D. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat. Neurosci., 2005, 8(4), 476-483.
37. Hannibal, J.; Jamen, F.; Nielsen, H.S.; Journot, L.; Brabet, P.; Fahrenkrug, J. Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J. Neurosci., 2001, 21(13), 4883-4890.
38. Colwell, C.S.; Michel, S.; Itri, J.; Rodriguez, W.; Tam, J.; Lelievre, V.; Hu, Z.; Waschek, J.A. Selective deficits in the circadian light response in mice lacking PACAP. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 287(5), R1194-R1201.
39. Kawaguchi, C.; Tanaka, K.; Isojima, Y.; Shintani, N.; Hashimoto, H.; Baba, A.; Nagai, K. Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. Biochem. Biophys. Res. Commun., 2003, 310(1), 169-175.
40. Asnicar, M.A.; Koster, A.; Heiman, M.L.; Tinsley, F.; Smith, D.P.; Galbreath, E.; Fox, N.; Ma, Y.L.; Blum, W.F.; Hsiung, H.M. Vasoactive intestinal polypeptide/pituitary adenylate cyclaseactivating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology, 2002, 143(10), 3994-4006.
41. Jamen, F.; Persson, K.; Bertrand, G.; Rodriguez-Henche, N.; Puech, R.; Bockaert, J.; Ahren, B.; Brabet, P. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J. Clin. Invest., 2000, 105(9), 1307-1315.
42. Persson, K.; Ahren, B. The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. Acta. Physiol. Scand., 2002, 175(1), 25-28.
43. Goetzl, E.J.; Voice, J.K.; Shen, S.; Dorsam, G.; Kong, Y.; West, K.M.; Morrison, C.F.; Harmar, A.J. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA, 2001, 98(24), 13854-13859.
44. Voice, J.K.; Dorsam, G.; Chan, R.C.; Grinninger, C.; Kong, Y.; Goetzl, E.J. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul. Pept., 2002, 109(1-3), 199-208.
45. Voice, J.K.; Grinninger, C.; Kong, Y.; Bangale, Y.; Paul, S.; Goetzl, E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol., 2003, 170(1), 308-314.
46. Martinez, C.; Abad, C.; Delgado, M.; Arranz, A.; Juarranz, M.G.; Rodriguez-Henche, N.; Brabet, P.; Leceta, J.; Gomariz, R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclaseactivating polypeptide receptor. Proc. Natl. Acad. Sci. USA, 2002, 99(2), 1053-1058.
47. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med., 2010, 362(4), 329-344.
48. Wenk, G.L. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry, 2003, 64(Suppl 9), 7-10.
49. Delgado, M.; Nieves, V.; Gonzalez-Rey, E. Vasoactive intestinal peptide protects against -amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia, 2008, 56(10), 1091-1103.
50. Gozes, I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci., 2001, 24(12), 700-705.
51. Offen, D.; Sherki, Y.; Melamed, E.; Fridkin, M.; Brenneman, D.E.; Gozes, I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res., 2000, 854(1-2), 257-262.
52. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79(4), 368-376.
53. Korkmaz O.T.; Tunçel, N.; Tunçel, M.; Oncü, E.M.; Sahintürk, V.; Celik, M. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J. Mol. Neurosci., 2009, 41(2), 278-287.
54. Delgado, M.; Ganea, D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J., 2003a, 17(13), 1922-1924.
55. Tunçel, N.; Sener, E.; Cerit, C.; Karasu, U.; Gürer, F.; Sahintürk, V.; Bayçu, C.; Ak, D.; Filiz, Z. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides, 2005, 26(5), 827-836.
56. Delgado, M.; Ganea, D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J., 2003b, 17(8), 944-946.
57. Newschaffer, C.J.; Croen, L.A.; Daniels, J.; Giarelli, E.; Grether, J.K.; Levy, S.E.; Mandell, D.S.; Miller, L.A.; Pinto-Martin, J.; Reaven, J.; Reynolds, A.M.; Rice, C.E.; Schendel, D.; Windham, G.C. The epidemiology of autism spectrum disorders. Ann. Rev. Public Health, 2007, 28, 235-258.
58. O'Roak, B.J.; State, M.W. Autism genetics: strategies, challenges, and opportunities. Autism Res., 2008, 1(1), 4-17.
59. Hill, J.M. Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. Curr. Pharm. Des., 2007, 13(11), 1079-1089.
60. Rodier, P.M.; Hyman, S.L. Early environmental factors in autism. Ment. Retard. Devel. Dis. Res. Rev., 1998, 4(2), 121-128.
61. Nelson, K.B.; Grether, J.K.; Croenn, L.A.; Dambrosia, J.M.; Dickens, B.F.; Jelliffe, L.L.; Hansen, R.L.; Phillips, T.M. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol., 2001, 49(5), 597-606.
62. Asano, E.; Kuivaniemi, H.; Huq, A.H.M.M., Tromp, G.; Behen, M.; Rothermel, R.; Herron, J.; Chugani, D.C. A study of novel polymorphisms in the upstream region of vasoactive intestinal peptide receptor type 2 gene in autism. J. Child. Neurol., 2001, 16(5), 357-363.